Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Increased appetite14.03.01.003; 08.01.09.0270.000392%Not Available
Influenza like illness08.01.03.010--
Injection site erythema12.07.03.001; 08.02.03.001; 23.03.06.0150.000606%Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.0050.000606%Not Available
Injection site mass12.07.03.010; 08.02.03.0090.000606%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.001212%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.001515%
Insomnia19.02.01.002; 17.15.03.0020.008612%
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Irritability19.04.02.013; 08.01.03.0110.005099%
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.000606%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000178%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.001302%
Libido decreased21.03.02.005; 19.08.03.0010.000909%
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.0040.000624%Not Available
Low density lipoprotein13.12.01.011--Not Available
Malabsorption07.17.01.001; 14.02.01.0040.001177%
Malaise08.01.01.0030.010430%
Mania19.16.02.0020.001141%
Memory impairment19.20.01.003; 17.03.02.0030.001836%
Menopausal symptoms21.02.02.002--Not Available
Mental impairment19.21.02.003; 17.03.03.0020.000446%Not Available
Middle insomnia19.02.01.003; 17.15.03.003--Not Available
Migraine24.03.05.003; 17.14.02.0010.001302%Not Available
Mood altered19.04.02.0070.001266%Not Available
Mood swings19.04.03.0010.001212%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.000178%Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.0050.000784%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 11 Pages